MARKET

RCUS

RCUS

Arcus Bioscience
NYSE
18.99
-0.49
-2.52%
After Hours: 18.43 -0.56 -2.95% 18:09 02/20 EST
OPEN
19.19
PREV CLOSE
19.48
HIGH
19.61
LOW
18.94
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
26.40
52 WEEK LOW
6.50
MARKET CAP
2.31B
P/E (TTM)
-5.5332
1D
5D
1M
3M
1Y
5Y
1D
Does Wells Fargo’s RCUS Downgrade Reveal Deeper Questions About Arcus Biosciences’ Casdatifan Strategy?
Simply Wall St · 6d ago
Weekly Report: what happened at RCUS last week (0209-0213)?
Weekly Report · 6d ago
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness
Simply Wall St · 02/13 05:25
Notable Thursday Option Activity: FSLY, GEO, RCUS
NASDAQ · 02/12 20:16
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Benzinga · 02/12 14:21
What Analysts Are Saying About Arcus Biosciences Stock
Benzinga · 02/12 14:00
Arcus Biosciences Price Target Cut to $23.00/Share From $30.00 by Wells Fargo
Dow Jones · 02/12 13:52
Arcus Biosciences Cut to Equal-Weight From Overweight by Wells Fargo
Dow Jones · 02/12 13:52
More
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Webull offers Arcus Biosciences Inc stock information, including NYSE: RCUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCUS stock methods without spending real money on the virtual paper trading platform.